

## Agenda

Saturday, 30th November 2013, 08:30 – 13:00



### From Neurobiology to Health Risks of RLS – Current Status of Research

Chairs: Ralf Kohnen & Juliane Winkelmann

08:30 – 08:35 **Welcome and Introduction**  
*Juliane Winkelmann*

#### Neurobiology of RLS

08:35 – 09:00 **RLS – Neurodevelopmental disorder: Evidence from genetic findings**  
*Juliane Winkelmann, Munich, Germany*

09:00 – 09:25 **RLS – Advances in brain imaging: Iron, dopamine, connectivity, volume, spectroscopy**  
*Giovanni Rizzo, Bologna, Italy*

09:25 – 09:50 **RLS - Interactions between dopamine and morphine signaling pathways in the spinal cord**  
*Stefan Clemens, Greenville, NC, USA*

09:50 – 10:15 **RLS – Spinal cord dysfunction: RLS and spinal cord excitability**  
*Cornelius Bachmann, Göttingen, Germany*

**10:15 – 10:35 Coffee Break**

#### Health Risks of RLS

10:35 – 11:00 **Risk of cardiovascular disease associated with RLS in the Kaiser Permanente Northern California cohort**  
*Stephen Van den Eeden, Oakland, USA*

11:00 – 11:25 **Time sequence between comorbid conditions and RLS: An egg and henn problem?**  
*Klaus Berger, Münster, Germany*

11:25 – 11:50 **Periodic Limb Movements and cardiovascular health**  
*Geert Mayer, Schwalmstadt-Treysa, Germany*

11:50 – 12:10 **Mental Health Risks and RLS: anxiety and depression**  
*Magdolna Hornyak, Munich, Germany*

12:10 – 12:30 **Examining the daily and long-term disease burden of RLS: what matters most and why**  
*Luigi Ferini-Strambi, Milan, Italy*

12:30 – 13:00: **Panel (all presenters) and Audience Discussion: is there a model which fits best both neurobiology and health risks of RLS?**  
*Moderator: Diego Garcia-Borreguero, Madrid, Spain*

EURLSSG-Meeting and Workshop are sponsored by:

F F. Hoffmann-La Roche Ltd., Mundipharma Research GmbH & Co KG, UCB Pharma S.A.,  
Vifor Pharma Deutschland GmbH, XenoPort Inc.



*We Innovate Healthcare*



 Vifor Pharma



<http://www.eurlssg.org>

[office@eurlssg.org](mailto:office@eurlssg.org)